Compared to normal kidney, RCC cells express higher levels of the more active isoform of GLS known as GAC, which is consistent with increased glutamine utilization thereby creating a therapeutic vulnerability to GLS inhibition [12, 15–17]. This evidence concerns the gene GLS and renal cell carcinoma.